NCT03669718 2023-12-29A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPCISA PharmaceuticalsPhase 2 Unknown194 enrolled
NCT05094804 2023-11-02A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsOncoResponse, Inc.Phase 1/2 Unknown172 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled